With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

By ADAM FEUERSTEIN

ADOBE

Clinical trial results give the company a shot at becoming the first drug to treat the condition — and possibly turn it into a blockbuster opportunity.

READ MORE